Colon cancer is the third most prevalent cancer for both men and women in the USA. It’s also the second most common cause of cancer-related deaths1—yet no two colon cancer patients, or their treatment needs, are the same.
The Oncotype DX Colon Recurrence Score test is clinically validated to quantify the risk of recurrence of patients with anatomic stage II, MMR-P and stage III A/B colon cancers.2-5 The 12-gene genomic test (seven cancer-related genes and five reference genes) looks at the underlying biology of a patient’s tumor—so you can choose a treatment that fits their unique situation.
Find out if your patient is eligible or order the test.
The Oncotype DX Colon Recurrence Score is the only genomic test for colon cancer with Level 1 evidence
Closing the gap in colon cancer management
The only genomic test for colon cancer with Level 1 evidence, the Colon Recurrence Score test gives you information that clinical and pathologic factors alone can’t provide. Developed over the course of multiple collaborative studies with both anatomic stage II and stage III patients, no other colon cancer multi-gene test is backed by as much data.
Performed on a tumor sample collected during your patient’s resection, the test looks at the activity of 12 genes in the tumor. The results are quantitative, reproducible, and offer an individualized assessment of risk for patients with either anatomic stage II, MMR-P or stage III A/B colon cancers.2-5
The Recurrence Score results provide a precise estimate of the risk of recurrence for anatomic stage II, MMR-P and stage III A/B patients to help guide the most appropriate treatment decision.2-5 For example:
- A high Recurrence Score result can identify anatomic stage II, MMR-P patients at higher risk of recurrence.2-5
- These patients may have a larger absolute benefit from chemotherapy.
- A low Recurrence Score result can identify anatomic stage III A/B patients at lower-than-average risk of recurrence.4,5
- These patients may have a smaller absolute benefit from the addition of oxaliplatin to fluorouracil and leucovorin (5-FU/LV).
Additionally, Genomic Health provides MMR testing using immunohistochemistry (IHC) to detect the protein expression of two MMR genes (MLH1 and MSH2). Used in conjunction with the Colon Recurrence Score test, MMR status offers deeper insight into the risk of recurrence beyond conventional measures.2-5
- Approximately 15% of stage II colon cancer patients with MMR-deficient (MMR-D) tumors have consistently been found to have a lower risk of recurrence.3,6
- Since stage II, MMR-D patients have a low baseline risk of recurrence, available data indicate that adjuvant chemotherapy may provide minimal if any clinical benefit.7 Therefore, a Colon Recurrence Score test is not performed.
The Colon Recurrence Score report includes the “Colon Recurrence Score result”, which is a number between 0-100. A low score means a lower chance of recurrence and a high score means a higher chance of recurrence.
This simple reference point makes talking to patients about their test results easy and efficient.
Learn more about Colon Recurrence Score results.
Evidence it works
Four validation studies—QUASAR, CALGB 9581, NSABP C-07, and SUNRISE—confirm that the Recurrence Score result predicts the risk of local recurrence.2-5 In addition, studies show that physicians regularly change treatment recommendations based on the test results.8-11 Get more details about these studies.
Impact of the test on treatment choices worldwide
More than 850,000 patients around the world have relied on the Oncotype DX tests for breast, colon, and prostate cancers to make better-informed treatment choices.